<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05018936</url>
  </required_header>
  <id_info>
    <org_study_id>HBP-NSAA-001</org_study_id>
    <nct_id>NCT05018936</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia</brief_title>
  <official_title>Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia: a Prospective Single Arm Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective one arm study to explore the efficacy and safety of Hetrombopag in&#xD;
      non-severe aplastic anemia. Patients meeting the inclusion and exclusion criteria would be&#xD;
      recruited. Treatment of Hetrombopag would be started with 5mg/day. The dosage would be&#xD;
      increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and&#xD;
      reduced if the platelet count reaches over than 150×10e9/L. The maximum dosage is 15mg/day.&#xD;
      All patients would receive treatment for at least 6 months except that the platelet&#xD;
      &lt;20×10e9/L at the dosage of 15mg/day for 4 weeks or the platelet ≥200×10e9/L at the dosage of&#xD;
      5mg/week for 2 weeks. The hematological response rate and safety will be recorded and&#xD;
      compared at D15, 1month, 1.5month, 2month, 3month, 4month, 5month, 6month, 8month, 10month&#xD;
      and 1year.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR at 6 Months</measure>
    <time_frame>6 month</time_frame>
    <description>Overall Response Rate (ORR) Defined as the Number of Participants Who Met the Criteria of Either Complete Response (CR) or Partial Response (PR) at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR at 3 Months</measure>
    <time_frame>3 month</time_frame>
    <description>ORR will be calculated after 3 months of treatment by measuring platelet, reticulocyte, neutrophil and transfusion independence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Platelet Transfusions</measure>
    <time_frame>12 months</time_frame>
    <description>Volume of Platelet Transfusions every month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of side effects at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>percentage of side effects would be recorded during the study and be calculated according to CTCAE 5.0 at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with clonal evolution at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients with clonal evolution would be evaluated by bone marrow biopsy at 12 months follow up.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Aplastic Anemia</condition>
  <condition>Drug Effect</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hetrombopag would be started with 5mg/day. The dosage would be increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L. The maximum dosage is 15mg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hetrombopag</intervention_name>
    <description>Hetrombopag starting at 5mg/day and increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L.</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients diagnosed to be non-severe aplastic anemia&#xD;
&#xD;
          2. Patients with platelet count &lt; 30×109/L and have at least one of the followings:&#xD;
             ①absolute neutrophil count &lt; 1.5×109/L, ②platelet count &lt; 50×109/L, ③ hemoglobin level&#xD;
             &lt; 100g/L&#xD;
&#xD;
          3. Patients have no response or relapsed following at least one treatment course in a&#xD;
             period time of &gt; 6 months of immunosuppression containing CsA or CsA+anti-thymocyte&#xD;
             globulin (ATG);&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2;&#xD;
&#xD;
          5. Patients able to understand and comply with protocol requirements and instructions and&#xD;
             have signed and dated informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Congenital aplastic anemia;&#xD;
&#xD;
          2. Presence of chromosomal aberration;&#xD;
&#xD;
          3. Evidence of a clonal hematologic bone marrow disorder (MDS, AML) on cytogenetics;&#xD;
&#xD;
          4. Presence with PNH clone ≥50%;&#xD;
&#xD;
          5. Patients received HSCT before;&#xD;
&#xD;
          6. Uncontrolled infection or bleeding with standard treatment;&#xD;
&#xD;
          7. Allergic to Hetrombopag or accessories;&#xD;
&#xD;
          8. HIV, HCV or HBV active infection or liver cirrhosis or portal hypertension;&#xD;
&#xD;
          9. Patient with QTcF (Fridericia's QT correction formula) at screening &lt;450 msec, or&lt;480&#xD;
             msec with bundle branch block, as determined via the mean of a triplicate ECG and&#xD;
             assessed at site, unstable angina pectoris, uncontrolled&#xD;
             hypertension(&gt;180/100mmHg)，pulmonary artery hypertension;&#xD;
&#xD;
         10. Have any concomitant malignancies within 5 years expect for local basal cell carcinoma&#xD;
             of the skin;&#xD;
&#xD;
         11. Past history of thromboembolic event, heart attack or stroke (including&#xD;
             anti-phospholipid antibody syndrome) and current use of anticoagulants;&#xD;
&#xD;
         12. Pregnant or nursing (lactating) woman;&#xD;
&#xD;
         13. Have attended other clinical trials within 3 months;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bing Han, Master</last_name>
    <role>Study Director</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bing Han, Docter</last_name>
    <phone>+8613601059938</phone>
    <email>hanbing_li@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Mei H, Liu X, Li Y, Zhou H, Feng Y, Gao G, Cheng P, Huang R, Yang L, Hu J, Hou M, Yao Y, Liu L, Wang Y, Wu D, Zhang L, Zheng C, Shen X, Hu Q, Liu J, Jin J, Luo J, Zeng Y, Gao S, Zhang X, Zhou X, Shi Q, Xia R, Xie X, Jiang Z, Gao L, Bai Y, Li Y, Xiong J, Li R, Zou J, Niu T, Yang R, Hu Y. A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. J Hematol Oncol. 2021 Feb 25;14(1):37. doi: 10.1186/s13045-021-01047-9.</citation>
    <PMID>33632264</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Bing Han</investigator_full_name>
    <investigator_title>Docter</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>individual participant data would be accepted upon request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>10 years</ipd_time_frame>
    <ipd_access_criteria>email request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

